Goldman Sachs initiated coverage on GRAIL with a Neutral rating following mixed trial results for its Galleri cancer test, which failed to meet its primary goal in an NHS study despite showing effectiveness in reducing Stage IV diagnoses. Subsequently, GRAIL faced class action lawsuits and investigations from multiple law firms regarding allegations of misleading investors. During the same period, legal actions and investigations were also launched against other companies, including Zoetis, Portillo's, and Verra Mobility.
